---
title: "Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Drug interactions questions"
description: "Drug interactions questions on Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What Kisqali dose is used with a strong CYP3A inhibitor? Can Kisqali be used with tamoxifen? Does Kisqali interact with letrozole, anastrozole, exemestane, or fulvestrant? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer: Drug interactions questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)

Drug interactions questions that apply to every indication of Kisqali are on [Kisqali (ribociclib), all indications: Drug interactions](https://www.evicenter.com/medical-information/kisqali/drug-interactions).

## Drug interactions

<a id="kisqali-strong-cyp3a-inhibitors"></a>

### What Kisqali dose is used with a strong CYP3A inhibitor?

> “Coadministration of strong CYP3A inhibitors increases ribociclib exposure [see Clinical Pharmacology (12.3)]. Increased 
> ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation [see 
> Warnings and Precautions (5.3)]. Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider 
> alternative concomitant medications with less potential for CYP3A inhibition.”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

> “In patients with advanced or metastatic breast cancer, if 
> coadministration of KISQALI with a strong CYP3A inhibitor cannot be avoided, reduce the dose of KISQALI to 400 mg 
> once daily”

Source: [KISQALI: Prescribing information, page 17, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=17)

> “If the strong inhibitor is discontinued, change the KISQALI dose (after at least 5 half-lives of the strong CYP3A inhibitor) 
> to the dose used prior to the initiation of the strong CYP3A inhibitor”

Source: [KISQALI: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=7)

> “CYP3A Inhibitors: Following a single 400 mg dose of KISQALI with ritonavir (a strong CYP3A inhibitor), ritonavir 
> (100 mg twice a day for 14 days) increased ribociclib Cmax and AUCinf by 1.7-fold and 3.2-fold, respectively, compared to 
> ribociclib alone.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

<a id="kisqali-tamoxifen"></a>

### Can Kisqali be used with tamoxifen?

Applies to: Pre- and perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer and no prior endocrine therapy for advanced disease, with a nonsteroidal aromatase inhibitor and goserelin (MONALEESA-7)

> “Avoid use of tamoxifen with KISQALI. In MONALEESA-7, the observed mean QTcF increase from baseline was > 10 ms 
> higher in the tamoxifen plus placebo subgroup compared with the non-steroidal aromatase inhibitors (NSAIs) plus placebo 
> subgroup. In the placebo arm, an increase of > 60 ms from baseline occurred in 6/90 (7%) of patients receiving tamoxifen, 
> and in no patients receiving an NSAI. An increase of > 60 ms from baseline in the QTcF interval was observed in 14/87 
> (16%) of patients in the KISQALI and tamoxifen combination and in 18/245 (7%) of patients receiving KISQALI plus an 
> NSAI [see Clinical Pharmacology (12.2)].”

Source: [KISQALI: Prescribing information, page 9, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=9)

> “Tamoxifen: KISQALI is not indicated for concomitant use with tamoxifen. Data from a clinical trial in patients with breast 
> cancer indicated that tamoxifen Cmax and AUC increased approximately 2-fold following coadministration of KISQALI 
> 600 mg.”

Source: [KISQALI: Prescribing information, page 22, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=22)

<a id="kisqali-endocrine-partner-interactions"></a>

### Does Kisqali interact with letrozole, anastrozole, exemestane, or fulvestrant?

> “Letrozole: Data from a clinical trial in patients with breast cancer indicated no drug interaction between ribociclib and 
> letrozole following coadministration of the drugs.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

> “Anastrozole: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between 
> ribociclib and anastrozole following coadministration of the drugs.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

> “Exemestane: Data from a clinical trial in patients with breast cancer indicated no clinically relevant drug interaction between 
> ribociclib and exemestane following coadministration of the drugs.”

Source: [KISQALI: Prescribing information, page 22, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=22)

> “Fulvestrant: Data from a clinical trial in patients with breast cancer indicated no clinically relevant effect of fulvestrant on 
> ribociclib exposure following coadministration of the drugs.”

Source: [KISQALI: Prescribing information, page 22, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=22)

## Related pages
- [Medical information: Kisqali (ribociclib): HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer/guidelines)
